Targovax ASA, announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer Annual Meeting being held November 6-10, 2019, in Maryland, USA.
October 9, 2019
· 1 min read